8/23/2013

Navidea Biopharmaceuticals has reached an agreement with the FDA regarding special-protocol assessments for Phase III trials for Navidea's investigational imaging agent NAV5001. The agent targets the brain's dopamine transporters for distinguishing Parkinsonian syndromes with SPECT imaging. Navidea plans to begin the trials this year.

Related Summaries